Me-too drug
A me-too drug is a medicine developed within an established therapeutic class, with similarities to an earlier medicine used for the same purpose. The term describes a relationship between products, not a conclusion that the later product is better or worse. Differences in selectivity, safety or interactions may still matter clinically.
Key takeaways
- Similarity does not establish therapeutic equivalence.
- A me-too drug is not necessarily a generic.
- Support comparative claims with relevant evidence.
Comparing Development Terms
An academic definition by Aronson and Green discusses structurally related medicines, including examples from statins and beta blockers. The FDA’s first-in-class description focuses on a mechanism of action different from existing therapies.
| Term | What it describes |
|---|---|
| First-in-class | A different mechanism from existing therapies. |
| Me-too | A later, related medicine in an established class. |
| Best-in-class | A comparative claim that needs a defined outcome and evidence. |
Why It Matters for Data Protection
Our recommendation is to separate the scientific development question from the data-use question. An established drug class is not, by itself, a justification for accessing another trial’s participant-level dataset. Before planning comparative analyses, document the proposed purpose, the data needed and the permissions and safeguards to be assessed. Avoid collecting additional identifiable information simply because a competitor studied it.
Hypothetical example: A biotech develops a new medicine in an established class and proposes a tolerability advantage. The team defines the population, comparator and relevant measurements before selecting datasets. Its privacy review then examines the proposed data access and reuse; the commercial description ‘me-too’ does not decide those questions.
Related reading: first-in-class drugs, best-in-class drugs. For practical support, see support for biotech and pharma sponsors.
Updated: 27 October 2026
No. Generic approval has requirements concerning the reference medicine, including the same active ingredient and demonstrated equivalence.
No. The label alone cannot establish relative benefit or risk.
Specify the comparator, endpoint and population, then review the supporting evidence and its limitations.
